-
胆碱是细胞膜的组成成分之一,肿瘤组织恶性增生增加了对胆碱的需求,肿瘤组织的胆碱摄取速率是反映细胞膜合成速率的指标,因而也是肿瘤细胞增殖的指标。11C-胆碱PET显像在脑瘤、肺癌、食道癌、结肠癌以及前列腺癌等恶性肿瘤中的诊断已取得了良好的效果[1-3]。虽然18F-FDG PET-CT显像获得了广泛应用,但在脑组织和盆腔内,18F-FDG不能有效区分肿瘤病灶与正常组织,有时还不能区分肿瘤与慢性炎症病灶。胆碱类显像剂与糖类显像剂的结合,可以弥补18F-FDG在前列腺癌、膀胱癌、脑肿瘤诊断中的不足[4]。由于11C的半衰期较短(20.4 min),使得11C-胆碱在临床上的应用受到限制,而18F具有较长的半衰期(109.8 min),可以满足多中心同时使用和较长时间显像等要求。(N-[18F]氟甲基)胆碱(18F-fluoromethyl choline,18F-FCH)是在结构上与11C-胆碱最为接近的化合物,在脑瘤和前列腺癌显像中已经表现出较好的应用前景[5]。
(N-[18F]氟甲基)胆碱的合成与质量控制
Synthesis and quality control of 18F-fluoromethyl choline
-
摘要:
目的 研究(N-[18F]氟甲基)胆碱(18F-FCH)在日本住友氟碳氮三合一合成装置上的全自动化合成与质量控制。 方法 由日本住友回旋加速器生产出来的18F-与CH2Br2反应生成中间产物18FCH2Br,在高温下通过Ag-Triflate/C柱对其活性进行改造,生成活性更强的18FC2H4SO3CF3,再与N, N-二甲基乙醇胺在Sep-Pak C-18柱上常温进行反应,分别用酒精、注射用水、生理盐水淋洗串联在一起的Sep-Pak C-18柱和Sep-Pak CM柱后纯化得到成品。通过高效液相色谱法对合成产品的放化纯度进行检测。 结果 合成产品的放化纯度>97%,未校正放化收率为27%,合成耗时38 min。 结论 此种合成方法过程简单、操作容易、产品质量稳定,并且合成效率及放化纯度均有所提高。 Abstract:Objective To research the automation synthesis and quality control of [18F]fluoromethyl choline(18F-FCH) by automatic synthesis module from Japanese sumitomo corporation. Methods Intermediate product 18FCH2Br was produced by the reaction of CH2Br2 with 18F- which was made by sumitomo cyclotron. 18FC2H4SO3CF3 with a higher activity was generated by modifying the activities of 18FCH2Br through the Ag-Triflate/C column at high temperature. 18FC2H4SO3CF3 reacted with N, N-dimethyl ethanolamine on Sep-Pak C-18 column at room temperature and the products were purified through washing the Sep-Pak C-18 column and Sep-Pak CM column in series with alcohol, water and physiological saline injector respectively. The purity of the final products was detected by high performance liquid chromatography. Results The radiochemical purity of 18F-FCH was above 97%, the uncorrected radiochemical yield was 27%, and the synthesis process last for 38 min. Conclusion This synthesis method has more advantages, such as easier operation, higher yields, shorter synthesis time, more stable products with a higher radiochemical purity. -
Key words:
- Cyclotron /
- Quality control /
- Fluoromethyl choline /
- Ag-Triflate
-
-
[1] Shao X, Hockley BG, Hoareau R, et al. Fully automated preparation of[11C] choline and[18F] fluoromethylcholine using TracerLab synthesis modules and facilitated quality control using analytical HPLC[J]. Appl Radiat Isot, 2011, 69(2): 403-409. doi: 10.1016/j.apradiso.2010.09.022 [2] Slaets D, De Bruyne S, Dumolyn C, et al. Reduced dimethylaminoethanol in [18F] fluoromethylcholine: an important step towards enhanced tumour visualization[J]. Eur J Nucl Med Mol Imaging, 2010, 37(11): 2136-2145. doi: 10.1007/s00259-010-1508-z [3] Piel M, Bauman A, Baum R, et al. Improved automated synthesis of[18F] fluoroethylcholine for prostate cancer imaging using PET/CT[J]. J Nucl Med, 2006, 47(Supple 1): 135-137. [4] Pascali G, D′Antonio L, Bovone P, et al. Optimization of automated large-scale production of [18F] fluoroethylcholine for PET prostate cancer imaging[J]. Nucl Med Biol, 2009, 36(5): 569-574. doi: 10.1016/j.nucmedbio.2009.01.004 [5] Piel M, Bauman A, Baum RP, et al. Improved automated synthesis of [18F]fluoroethylcholine as a radiotracer for cancer imaging[J]. Bioorg Med Chem, 2007, 15(9): 3171-3175. doi: 10.1016/j.bmc.2007.02.038 [6] Li Z, Vance DE. Phosphatidylcholine and choline homeostasis[J]. J Lipid Res, 2008, 49(6): 1187-1194. doi: 10.1194/jlr.R700019-JLR200 [7] 周丽娜, 吴宁. PET/CT新型分子显像剂在肿瘤个体化药物治疗中的应用[J].国际医学放射学杂志, 2011, 34(1): 61-64. doi: 10.3784/j.issn.1674-1897.2011.01.Z0112
[8] Zhang H, Tian M, Oriuchi N, et al. 11C-choline PET for the detection of bone and soft tissue tumours in comparison with FDG PET[J]. Nucl Med Commun, 2003, 24(3): 273-279. [9] Kwee SA, DeGrado TR, Talbot JN, et al. Cancer imaging with fluorine-18-labeled choline derivatives[J]. Semin Nucl Med, 2007, 37(6): 420-428. doi: 10.1053/j.semnuclmed.2007.07.003